BROADPRO BIOTECH INC

Broad Institute is a multidisciplinary community of researchers on a mission to improve human health.

Slow-growing glioma tumors become more aggressive when their cells shift identities and acquire new genetic mutations.

We are a research organization dedicated to better understanding the roots of disease and narrowing the gap between new biological insights and impact for patients.

Associate and Affiliate Members

Professional scientists

Early career scientists

Partner institutions

Our scientists are probing the mechanisms of cancer and applying this knowledge to enable precision cancer medicine.

Cardiovascular disease

By applying a variety of tools and technologies, researchers here are working to reduce the burden of cardiovascular disease.

Our researchers study the cellular roles and physiological impacts of genes associated with type 2 diabetes.

Infectious disease and the microbiome

Researchers across the institute are working to understand infectious diseases, antibiotic resistance, and the human microbiome.

Our scientists are cataloging the molecular causes of kidney diseases in order to develop mechanism-based treatments.

By studying the genetic determinants of body weight, our researchers work to identify targets for future obesity therapies.

Psychiatric disorders

We are committed to characterizing psychiatric disorders' molecular roots and turning new findings into new treatments.

Our scientists search for the risk factors underlying rare genetic diseases to help reveal their biological underpinnings and improve patients' lives.

Cardiovascular disease

Infectious disease and the microbiome

Psychiatric disorders

Chemical biology and therapeutics science

We are fostering a diverse research community engaged in innovative chemical biology and therapeutic research.

Our Center for the Development of Therapeutics (CDoT) helps scientists advance biological insights to new treatments.

Genome regulation, cellular circuitry, and epigenomics

Our scientists are charting the vast landscape of molecular elements that define and regulate the cell.

Researchers across Broad are defining the immune cells and pathways that regulate physiologic and pathologic processes.

Medical and population genetics

An array of scientists here are collaborating to establish genomic variations' roles in human traits and disorders.

Our researchers aim to decipher the metabolic basis of rare and common human diseases.

Chemical biology and therapeutics science

Genome regulation, cellular circuitry, and epigenomics

Medical and population genetics

Members of the Data Sciences Platform build open-source technologies that help researchers everywhere connect to the patients, datasets, and tools they need to do life-changing science.

Genetic perturbation

The Genetic Perturbation Platform drives the functional study of the genome by developing groundbreaking technologies for perturbing genes at scale.

Genomic scientists here at Broad create foundational resources and study the genomic basis of human traits and diseases.

Computationally mining cellular images' rich information content can propel discoveries in biology and medicine.

Cells' metabolites reveal unique chemical fingerprints of both normal and pathological disease processes.

Broad proteomic researchers address important questions in biology, chemistry, and clinical science through collaboration and technology development.

Genetic perturbation

Broad Discovery Series: Moving from "hit-or-miss" toward a brighter future for psychiatric diagnosis and care

Visit the Broad Discovery Center

Learn about summer research programs for students

Merkin Building
415 Main St.
Cambridge, MA 02142

Sign up for our newsletter

In March of 2020, Broad Institute converted a clinical genetics processing lab into a large-scale COVID-19 testing facility in less than two weeks.

We've screened more than 1,275 cancer cell lines as part of the Cancer Dependency Map (DepMap).

Broad Genomics Platform sequences a whole human genome every four minutes.

More than 11,000 individuals living with cancer in the United States and Canada have partnered with Count Me In to share their experiences and help accelerate cancer research.

The Drug Repurposing Hub is one of the most comprehensive and up-to-date biologically annotated collections of FDA-approved compounds in the world. Researchers anywhere can explore more than 6,000 drugs in the hub and search for possible new uses for them to jump-start new drug discovery.

In 2021, our sustainability efforts sent more than 80 percent of waste from the Genomics Platform to either a recycling facility or to an incineration plant that generates electricity.

Through Broad's Scientists in the Classroom program, Broad researchers visit every 8th grade classroom in Cambridge each year to talk about genetics and evolution.

Every summer, 18 high school students spend six weeks at Broad working side-by-side with mentors on cutting-edge research.